Reflux Esophagitis Phase III Study (Maintenance Treatment)
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of esomeprazole 20 mg once
daily for 24 weeks on maintenance of Reflux Esophagitis in patients with healed reflux
esophagitis in comparison with omeprazole 10 mg once daily and esomeprazole 10 mg once daily
by assessment of presence/absence of recurrence of Reflux Esophagitis throughout the
treatment period (from the randomisation to the treatment completion) according to the Los
Angeles classification.